EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Synthesis of BODIPY-TKI Conjugates and Investigation of Their Ability to Target the Epidermal Growth Factor Receptor

Simran Dhingra iD, Prajesh Shrestha iD, Arpan Chowdhury, Zehua Zhou, Seetharama D Jois, Maria da Graça H Vicente iD

Targets · 2023

DOI: 10.3390/targets1010005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targets, 2023. Verfasst von Simran Dhingra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Science Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A near-IR BODIPY was covalently conjugated via its isothiocyanate groups to one or two Erlotinib molecules, a known tyrosine kinase inhibitor (TKI), via triethylene glycol spacers, to produce two novel BODIPY-monoTKI and BODIPY-diTKI conjugates. The ability of these conjugates to target the intracellular domain of the epidermal growth factor receptor (EGFR) was investigated using molecular modeling, surface plasma resonance (SPR), EGFR kinase binding assay, time-dependent cellular uptake, and fluorescence microscopy. While both the BODIPY-monoTKI and the BODIPY-diTKI conjugates were shown to bind to the EGFR kinase by SPR and accumulated more efficiently within human HEp2 cells that over-express EGFR than BODIPY alone, only the BODIPY-monoTKI exhibited kinase inhibition activity. This is due to the high hydrophobic character and aggregation behavior of the BODIPY-diTKI in aqueous solutions, as shown by fluorescence quenching. Furthermore, the competition of the two Erlotinibs in the diTKI conjugate for the active site of the kinase, as suggested by computational modeling, might lead to a decrease in binding relative to the monoTKI conjugate. Nevertheless, the efficient cellular uptake and intracellular localization of both conjugates with no observed cytotoxicity suggest that both could be used as near-IR fluorescent markers for cells that over-express EGFR.

Schlagwörter

Stichwörter der Autor:innen

BODIPYEGFR bindingSPRTKIcomputational modelingerlotinibmicroscopy

Autor:innen und Institutionen

  • Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA.
  • Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
  • School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.

ORCID-Profile: Simran Dhingra, Prajesh Shrestha, Maria da Graça H Vicente

Förderung

  • NCI NIH HHS
  • National Science Foundation
  • National Institutes of Health

Zitieren

APA

Dhingra, S., Shrestha, P., Chowdhury, A., Zhou, Z., Jois, S. D., & Vicente, M. D. G. H. (2023). The Synthesis of BODIPY-TKI Conjugates and Investigation of Their Ability to Target the Epidermal Growth Factor Receptor. Targets. https://doi.org/10.3390/targets1010005

Vancouver

Dhingra S, Shrestha P, Chowdhury A, Zhou Z, Jois SD, Vicente MDGH. The Synthesis of BODIPY-TKI Conjugates and Investigation of Their Ability to Target the Epidermal Growth Factor Receptor. Targets. 2023. doi:10.3390/targets1010005

BibTeX
@article{Dhingra2023,
  author = {Dhingra, Simran and Shrestha, Prajesh and Chowdhury, Arpan and Zhou, Zehua and Jois, Seetharama D and Vicente, Maria da Graça H},
  title = {The Synthesis of BODIPY-TKI Conjugates and Investigation of Their Ability to Target the Epidermal Growth Factor Receptor},
  journal = {Targets},
  year = {2023},
  doi = {10.3390/targets1010005}
}
Kostenlos starten →